Vivos Therapeutics, Inc. (NASDAQ:VVOS) Given Consensus Rating of “Hold” by Analysts

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $4.9167.

A number of brokerages recently commented on VVOS. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Ascendiant Capital Markets lowered their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st.

Institutional Trading of Vivos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in Vivos Therapeutics in the 2nd quarter worth about $65,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the 2nd quarter valued at about $220,000. Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics during the third quarter valued at about $620,000. Acorn Wealth Advisors LLC bought a new stake in shares of Vivos Therapeutics during the fourth quarter valued at about $30,000. Finally, DRW Securities LLC lifted its holdings in shares of Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares in the last quarter. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $1.22 on Friday. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The company has a market cap of $12.77 million, a PE ratio of -0.69 and a beta of 6.94. Vivos Therapeutics has a 52 week low of $1.19 and a 52 week high of $7.95. The firm’s 50-day simple moving average is $1.59 and its two-hundred day simple moving average is $2.31.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.